Skip to main content
Top
Published in: BMC Nephrology 1/2016

Open Access 01-12-2016 | Research article

Association of peripheral arterial disease with all-cause and cardiovascular mortality in hemodialysis patients: a meta-analysis

Authors: Yi Yang, Yong Ning, Weifeng Shang, Ran Luo, Lixi Li, Shuiming Guo, Gang Xu, Xiaofeng He, Shuwang Ge

Published in: BMC Nephrology | Issue 1/2016

Login to get access

Abstract

Background

Recent studies have shown an association between peripheral arterial disease (PAD) and increased risk of mortality in hemodialysis (HD) patients; however, the estimates vary widely and are inconsistent. It is necessary to elucidate the degree of mortality risk for PAD patients in HD population.

Methods

PubMed, EMBASE, Web of Science and Cochrane Library (from inception to September 4th, 2016) were systematically searched for cohort studies assessing the association between PAD and mortality in HD patients. We calculated the pooled risk ratios (RRs) with 95% confidence intervals (CI) of all-cause and cardiovascular (CV) mortality using random effects models. Subgroup analyses were conducted to explore the source of heterogeneity.

Results

The search identified 2,973 potentially eligible records and 10 studies (n = 32,864) were included. Our meta-analysis revealed that PAD significantly increased the risk of all-cause mortality (RR 2.15, 95 % CI 1.67–2.77, n = 32,864) and CV mortality (RR 2.99, 95 % CI 1.66-5.38, n = 31,794) in HD patients after multivariate adjustment. Subgroup analyses showed the study design and follow-up time might be two sources of heterogeneity.

Conclusion

PAD may be a prognostic marker of all-cause and CV mortality in HD patients. More attention should be paid to diagnosis and management of PAD in HD patients.
Appendix
Available only for authorised users
Literature
1.
go back to reference Robinson BM, Akizawa T, Jager KJ, Kerr PG, Saran R, Pisoni RL. Factors affecting outcomes in patients reaching end-stage kidney disease worldwide: differences in access to renal replacement therapy, modality use, and haemodialysis practices. Lancet. 2016;388(10041):294–306.CrossRefPubMed Robinson BM, Akizawa T, Jager KJ, Kerr PG, Saran R, Pisoni RL. Factors affecting outcomes in patients reaching end-stage kidney disease worldwide: differences in access to renal replacement therapy, modality use, and haemodialysis practices. Lancet. 2016;388(10041):294–306.CrossRefPubMed
2.
go back to reference Masakane I, Nakai S, Ogata S, Kimata N, Hanafusa N, Hamano T, Wakai K, Wada A, Nitta K. An overview of regular dialysis treatment in Japan (as of 31 December 2013). Ther Apher Dial. 2015;19(6):540–74.CrossRefPubMed Masakane I, Nakai S, Ogata S, Kimata N, Hanafusa N, Hamano T, Wakai K, Wada A, Nitta K. An overview of regular dialysis treatment in Japan (as of 31 December 2013). Ther Apher Dial. 2015;19(6):540–74.CrossRefPubMed
3.
go back to reference Yan G, Norris KC, Xin W, Ma JZ, Yu AJ, Greene T, Yu W, Cheung AK. Facility size, race and ethnicity, and mortality for in-center hemodialysis. J Am Soc Nephrol. 2013;24(12):2062–70.CrossRefPubMedPubMedCentral Yan G, Norris KC, Xin W, Ma JZ, Yu AJ, Greene T, Yu W, Cheung AK. Facility size, race and ethnicity, and mortality for in-center hemodialysis. J Am Soc Nephrol. 2013;24(12):2062–70.CrossRefPubMedPubMedCentral
4.
go back to reference Bellasi A, Kooienga L, Block GA, Veledar E, Spiegel DM, Raggi P. How long is the warranty period for nil or low coronary artery calcium in patients new to hemodialysis? J Nephrol. 2009;22(2):255–62.PubMed Bellasi A, Kooienga L, Block GA, Veledar E, Spiegel DM, Raggi P. How long is the warranty period for nil or low coronary artery calcium in patients new to hemodialysis? J Nephrol. 2009;22(2):255–62.PubMed
5.
go back to reference Stenvinkel P, Heimburger O, Paultre F, Diczfalusy U, Wang T, Berglund L, Jogestrand T. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int. 1999;55(5):1899–911.CrossRefPubMed Stenvinkel P, Heimburger O, Paultre F, Diczfalusy U, Wang T, Berglund L, Jogestrand T. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int. 1999;55(5):1899–911.CrossRefPubMed
6.
go back to reference Patel MR, Conte MS, Cutlip DE, Dib N, Geraghty P, Gray W, Hiatt WR, Ho M, Ikeda K, Ikeno F, et al. Evaluation and treatment of patients with lower extremity peripheral artery disease: consensus definitions from Peripheral Academic Research Consortium (PARC). J Am Coll Cardiol. 2015;65(9):931–41.CrossRefPubMedPubMedCentral Patel MR, Conte MS, Cutlip DE, Dib N, Geraghty P, Gray W, Hiatt WR, Ho M, Ikeda K, Ikeno F, et al. Evaluation and treatment of patients with lower extremity peripheral artery disease: consensus definitions from Peripheral Academic Research Consortium (PARC). J Am Coll Cardiol. 2015;65(9):931–41.CrossRefPubMedPubMedCentral
7.
go back to reference Krishna SM, Moxon JV, Golledge J. A review of the pathophysiology and potential biomarkers for peripheral artery disease. Int J Mol Sci. 2015;16(5):11294–322.CrossRefPubMedPubMedCentral Krishna SM, Moxon JV, Golledge J. A review of the pathophysiology and potential biomarkers for peripheral artery disease. Int J Mol Sci. 2015;16(5):11294–322.CrossRefPubMedPubMedCentral
8.
go back to reference Fishbane S, Youn S, Flaster E, Adam G, Maesaka JK. Ankle-arm blood pressure index as a predictor of mortality in hemodialysis patients. Am J Kidney Dis. 1996;27(5):668–72.CrossRefPubMed Fishbane S, Youn S, Flaster E, Adam G, Maesaka JK. Ankle-arm blood pressure index as a predictor of mortality in hemodialysis patients. Am J Kidney Dis. 1996;27(5):668–72.CrossRefPubMed
9.
go back to reference Ono K. Ankle-brachial blood pressure index predicts All-cause and cardiovascular mortality in hemodialysis patients. J Am Soc Nephrol. 2003;14(6):1591–8.CrossRefPubMed Ono K. Ankle-brachial blood pressure index predicts All-cause and cardiovascular mortality in hemodialysis patients. J Am Soc Nephrol. 2003;14(6):1591–8.CrossRefPubMed
10.
go back to reference Rajagopalan S, Dellegrottaglie S, Furniss AL, Gillespie BW, Satayathum S, Lameire N, Saito A, Akiba T, Jadoul M, Ginsberg N, et al. Peripheral arterial disease in patients with end-stage renal disease: observations from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Circulation. 2006;114(18):1914–22.CrossRefPubMed Rajagopalan S, Dellegrottaglie S, Furniss AL, Gillespie BW, Satayathum S, Lameire N, Saito A, Akiba T, Jadoul M, Ginsberg N, et al. Peripheral arterial disease in patients with end-stage renal disease: observations from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Circulation. 2006;114(18):1914–22.CrossRefPubMed
11.
go back to reference Cohen LM, Ruthazer R, Moss AH, Germain MJ. Predicting six-month mortality for patients who are on maintenance hemodialysis. Clin J Am Soc Nephrol. 2010;5(1):72–9.CrossRefPubMedPubMedCentral Cohen LM, Ruthazer R, Moss AH, Germain MJ. Predicting six-month mortality for patients who are on maintenance hemodialysis. Clin J Am Soc Nephrol. 2010;5(1):72–9.CrossRefPubMedPubMedCentral
12.
go back to reference Adragao T, Pires A, Branco P, Castro R, Oliveira A, Nogueira C, Bordalo J, Curto JD, Prata MM. Ankle--brachial index, vascular calcifications and mortality in dialysis patients. Nephrol Dial Transplant. 2012;27(1):318–25.CrossRefPubMed Adragao T, Pires A, Branco P, Castro R, Oliveira A, Nogueira C, Bordalo J, Curto JD, Prata MM. Ankle--brachial index, vascular calcifications and mortality in dialysis patients. Nephrol Dial Transplant. 2012;27(1):318–25.CrossRefPubMed
13.
go back to reference Otsubo S, Kitamura M, Wakaume T, Yajima A, Ishihara M, Takasaki M, Ueda S, Sugimoto H, Otsubo K, Kimata N, et al. Association of peripheral artery disease and long-term mortality in hemodialysis patients. Int Urol Nephrol. 2012;44(2):569–73.CrossRefPubMed Otsubo S, Kitamura M, Wakaume T, Yajima A, Ishihara M, Takasaki M, Ueda S, Sugimoto H, Otsubo K, Kimata N, et al. Association of peripheral artery disease and long-term mortality in hemodialysis patients. Int Urol Nephrol. 2012;44(2):569–73.CrossRefPubMed
14.
go back to reference Al Thani H, El-Menyar A, Hussein A, Sadek A, Sharaf A, Singh R, Koshy V, Al Suwaidi J. Prevalence, predictors, and impact of peripheral arterial disease in hemodialysis patients: a cohort study with a 3-year follow-up. Angiology. 2013;64(2):98–104.CrossRefPubMed Al Thani H, El-Menyar A, Hussein A, Sadek A, Sharaf A, Singh R, Koshy V, Al Suwaidi J. Prevalence, predictors, and impact of peripheral arterial disease in hemodialysis patients: a cohort study with a 3-year follow-up. Angiology. 2013;64(2):98–104.CrossRefPubMed
15.
go back to reference Tsai MH, Liou HH, Leu JG, Yen MF, Chen HH. Sites of peripheral artery occlusive disease as a predictor for all-cause and cardiovascular mortality in chronic hemodialysis. PLoS One. 2015;10(6):e0128968.CrossRefPubMedPubMedCentral Tsai MH, Liou HH, Leu JG, Yen MF, Chen HH. Sites of peripheral artery occlusive disease as a predictor for all-cause and cardiovascular mortality in chronic hemodialysis. PLoS One. 2015;10(6):e0128968.CrossRefPubMedPubMedCentral
16.
go back to reference Zhou Y, Zhang J, Zhu M, Lu R, Wang Y, Ni Z. Plasma pentraxin 3 is closely associated with peripheral arterial disease in hemodialysis patients and predicts clinical outcome: a 6-year follow-Up. Blood Purif. 2015;39(4):266–73.CrossRefPubMed Zhou Y, Zhang J, Zhu M, Lu R, Wang Y, Ni Z. Plasma pentraxin 3 is closely associated with peripheral arterial disease in hemodialysis patients and predicts clinical outcome: a 6-year follow-Up. Blood Purif. 2015;39(4):266–73.CrossRefPubMed
17.
go back to reference Vega A, Pérez García R, Abad S, Verde E, López Gómez JM, Jofré R, Puerta M, Rodríguez P. Enfermedad vascular periférica: prevalencia, mortalidad y asociación con inflamación en hemodiálisis. Nefrología. 2008;28(3):311–6.PubMed Vega A, Pérez García R, Abad S, Verde E, López Gómez JM, Jofré R, Puerta M, Rodríguez P. Enfermedad vascular periférica: prevalencia, mortalidad y asociación con inflamación en hemodiálisis. Nefrología. 2008;28(3):311–6.PubMed
18.
go back to reference Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264–9. W264.CrossRefPubMed Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264–9. W264.CrossRefPubMed
21.
22.
go back to reference Dua A, Lee CJ. Epidemiology of Peripheral Arterial Disease and Critical Limb Ischemia. Tech Vasc Interv Radiol. 2016;19(2):91–5.CrossRefPubMed Dua A, Lee CJ. Epidemiology of Peripheral Arterial Disease and Critical Limb Ischemia. Tech Vasc Interv Radiol. 2016;19(2):91–5.CrossRefPubMed
23.
24.
go back to reference Sharif MR, Chitsazian Z, Moosavian M, Raygan F, Nikoueinejad H, Sharif AR, Einollahi B. Immune disorders in hemodialysis patients. Iran J Kidney Dis. 2015;9(2):84–96.PubMed Sharif MR, Chitsazian Z, Moosavian M, Raygan F, Nikoueinejad H, Sharif AR, Einollahi B. Immune disorders in hemodialysis patients. Iran J Kidney Dis. 2015;9(2):84–96.PubMed
25.
go back to reference Stenvinkel P. Inflammatory and atherosclerotic interactions in the depleted uremic patient. Blood Purif. 2001;19(1):53–61.CrossRefPubMed Stenvinkel P. Inflammatory and atherosclerotic interactions in the depleted uremic patient. Blood Purif. 2001;19(1):53–61.CrossRefPubMed
26.
go back to reference Ozaki Y, Imanishi T, Akasaka T. Inflammatory biomarkers in peripheral artery disease: diagnosis, prognosis, and therapeutic challenges. Curr Med Chem. 2015;22(23):2744–53.CrossRefPubMed Ozaki Y, Imanishi T, Akasaka T. Inflammatory biomarkers in peripheral artery disease: diagnosis, prognosis, and therapeutic challenges. Curr Med Chem. 2015;22(23):2744–53.CrossRefPubMed
27.
go back to reference Stone PA, Yacoub M. Inflammatory biomarkers in peripheral arterial disease. Semin Vasc Surg. 2014;27(3–4):148–51.CrossRefPubMed Stone PA, Yacoub M. Inflammatory biomarkers in peripheral arterial disease. Semin Vasc Surg. 2014;27(3–4):148–51.CrossRefPubMed
28.
go back to reference Fung ET, Wilson AM, Zhang F, Harris N, Edwards KA, Olin JW, Cooke JP. A biomarker panel for peripheral arterial disease. Vasc Med. 2008;13(3):217–24.CrossRefPubMedPubMedCentral Fung ET, Wilson AM, Zhang F, Harris N, Edwards KA, Olin JW, Cooke JP. A biomarker panel for peripheral arterial disease. Vasc Med. 2008;13(3):217–24.CrossRefPubMedPubMedCentral
29.
go back to reference Hiatt WR, Zakharyan A, Fung ET, Crutcher G, Smith A, Stanford C, Cooke J. A validated biomarker panel to identify peripheral artery disease. Vasc Med. 2012;17(6):386–93.CrossRefPubMed Hiatt WR, Zakharyan A, Fung ET, Crutcher G, Smith A, Stanford C, Cooke J. A validated biomarker panel to identify peripheral artery disease. Vasc Med. 2012;17(6):386–93.CrossRefPubMed
30.
go back to reference Kals J, Zagura M, Serg M, Kampus P, Zilmer K, Unt E, Lieberg J, Eha J, Peetsalu A, Zilmer M. beta2-microglobulin, a novel biomarker of peripheral arterial disease, independently predicts aortic stiffness in these patients. Scand J Clin Lab Invest. 2011;71(4):257–63.CrossRefPubMed Kals J, Zagura M, Serg M, Kampus P, Zilmer K, Unt E, Lieberg J, Eha J, Peetsalu A, Zilmer M. beta2-microglobulin, a novel biomarker of peripheral arterial disease, independently predicts aortic stiffness in these patients. Scand J Clin Lab Invest. 2011;71(4):257–63.CrossRefPubMed
32.
go back to reference Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. Jama. 2001;285(19):2481–5.CrossRefPubMed Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. Jama. 2001;285(19):2481–5.CrossRefPubMed
33.
go back to reference Kielstein JT, Zoccali C. Asymmetric dimethylarginine: a cardiovascular risk factor and a uremic toxin coming of age? Am J Kidney Dis. 2005;46(2):186–202.CrossRefPubMed Kielstein JT, Zoccali C. Asymmetric dimethylarginine: a cardiovascular risk factor and a uremic toxin coming of age? Am J Kidney Dis. 2005;46(2):186–202.CrossRefPubMed
34.
go back to reference Reis JP, von Mühlen D, Michos ED, Miller ER, Appel LJ, Araneta MR, Barrett-Connor E. Serum vitamin D, parathyroid hormone levels, and carotid atherosclerosis. Atherosclerosis. 2009;207(2):585–90.CrossRefPubMedPubMedCentral Reis JP, von Mühlen D, Michos ED, Miller ER, Appel LJ, Araneta MR, Barrett-Connor E. Serum vitamin D, parathyroid hormone levels, and carotid atherosclerosis. Atherosclerosis. 2009;207(2):585–90.CrossRefPubMedPubMedCentral
35.
go back to reference Cheung AK, Sarnak MJ, Yan G, Dwyer JT, Heyka RJ, Rocco MV, Teehan BP, Levey AS. Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int. 2000;58(1):353–62.CrossRefPubMed Cheung AK, Sarnak MJ, Yan G, Dwyer JT, Heyka RJ, Rocco MV, Teehan BP, Levey AS. Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int. 2000;58(1):353–62.CrossRefPubMed
36.
go back to reference Olin JW, White CJ, Armstrong EJ, Kadian-Dodov D, Hiatt WR. Peripheral artery disease: evolving role of exercise, medical therapy, and endovascular options. J Am Coll Cardiol. 2016;67(11):1338–57.CrossRefPubMed Olin JW, White CJ, Armstrong EJ, Kadian-Dodov D, Hiatt WR. Peripheral artery disease: evolving role of exercise, medical therapy, and endovascular options. J Am Coll Cardiol. 2016;67(11):1338–57.CrossRefPubMed
37.
go back to reference Antithrombotic Trialists C. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324(7329):71–86.CrossRef Antithrombotic Trialists C. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324(7329):71–86.CrossRef
38.
go back to reference Group HPSC. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial. The Lancet. 2002;360(9326):7–22. Group HPSC. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial. The Lancet. 2002;360(9326):7–22.
39.
go back to reference Heart Protection Study Collaborative G. Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. J Vasc Surg. 2007;45(4):645–54. discussion 653–644.CrossRef Heart Protection Study Collaborative G. Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. J Vasc Surg. 2007;45(4):645–54. discussion 653–644.CrossRef
40.
go back to reference Armstrong EJ, Wu J, Singh GD, Dawson DL, Pevec WC, Amsterdam EA, Laird JR. Smoking cessation is associated with decreased mortality and improved amputation-free survival among patients with symptomatic peripheral artery disease. J Vasc Surg. 2014;60(6):1565–71.CrossRefPubMed Armstrong EJ, Wu J, Singh GD, Dawson DL, Pevec WC, Amsterdam EA, Laird JR. Smoking cessation is associated with decreased mortality and improved amputation-free survival among patients with symptomatic peripheral artery disease. J Vasc Surg. 2014;60(6):1565–71.CrossRefPubMed
41.
go back to reference Ohtake T, Sato M, Nakazawa R, Kondoh M, Miyaji T, Moriya H, Hidaka S, Kobayashi S. Randomized pilot trial between prostaglandin I2 analog and anti-platelet drugs on peripheral arterial disease in hemodialysis patients. Ther Apher Dial. 2014;18(1):1–8.CrossRefPubMed Ohtake T, Sato M, Nakazawa R, Kondoh M, Miyaji T, Moriya H, Hidaka S, Kobayashi S. Randomized pilot trial between prostaglandin I2 analog and anti-platelet drugs on peripheral arterial disease in hemodialysis patients. Ther Apher Dial. 2014;18(1):1–8.CrossRefPubMed
42.
go back to reference Al-Thani H, Shabana A, Hussein A, Sadek A, Sharaf A, Koshy V, El-Menyar A. Cardiovascular complications in diabetic patients undergoing regular hemodialysis: a 5-year observational study. Angiology. 2015;66(3):225–30.CrossRefPubMed Al-Thani H, Shabana A, Hussein A, Sadek A, Sharaf A, Koshy V, El-Menyar A. Cardiovascular complications in diabetic patients undergoing regular hemodialysis: a 5-year observational study. Angiology. 2015;66(3):225–30.CrossRefPubMed
Metadata
Title
Association of peripheral arterial disease with all-cause and cardiovascular mortality in hemodialysis patients: a meta-analysis
Authors
Yi Yang
Yong Ning
Weifeng Shang
Ran Luo
Lixi Li
Shuiming Guo
Gang Xu
Xiaofeng He
Shuwang Ge
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2016
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/s12882-016-0397-1

Other articles of this Issue 1/2016

BMC Nephrology 1/2016 Go to the issue